OrbiMed forms biotech with assets from China-based Keymed, enlists former Biohaven exec as CEO

Kyle LaHucik

Senior Reporter

OrbiMed, a longtime biotech funder, created a startup with two bispecific antibodies licensed from a drugmaker in China and put a former Biohaven executive at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

OrbiMed forms biotech with assets from China-based Keymed, enlists former Biohaven exec as CEO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Or­biMed forms biotech with as­sets from Chi­na-based Keymed, en­lists for­mer Bio­haven ex­ec as CEO

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

OrbiMed forms biotech with assets from China-based Keymed, enlists former Biohaven exec as CEO